BIO 2026: As ADCs evolve, experts say ‘wellness’ needs to be factored into patient survival

ConferenceAntibody-drug conjugatesNeutral

AI Analysis

Summary

At BIO 2026, experts discuss the evolution of antibody-drug conjugates and emphasize that developers must create therapies that improve patient wellness alongside survival as ADCs move into earlier treatment lines.

Importance:2/10

Sentiment:

0.00

ADCantibody-drug conjugatespatient outcomesBIO 2026drug development

Read the original article

Published by BioSpace on July 13, 2026 12:57 PM

Read Original